|1.||Cox, Manon M J: 3 articles (11/2015 - 09/2014)|
|2.||Izikson, Ruvim: 3 articles (11/2015 - 10/2011)|
|3.||Post, Penny: 2 articles (11/2015 - 07/2015)|
|4.||Patriarca, Peter A: 1 article (11/2015)|
|5.||Bock, S Allan: 1 article (11/2015)|
|6.||Leffell, David J: 1 article (11/2015)|
|7.||Dunkle, Lisa M: 1 article (11/2015)|
|8.||Dunkle, Lisa: 1 article (07/2015)|
|9.||Kubera, Paul: 1 article (09/2014)|
|10.||Meghrous, Jamal: 1 article (09/2014)|
|1.||Human Influenza (Influenza)
08/01/2013 - "In a large, placebo-controlled, phase III trial in individuals aged 18-49 years, Flublok(®) met the US FDA requirements for immunogenicity, effectiveness and safety, despite a high incidence of antigenic mismatch between confirmed cases of influenza and the vaccine component strains. "
07/01/2015 - "Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults."
09/22/2014 - "The successful development, technology transfer and scale-up of the Flublok process has major implications for being ready to make vaccine rapidly on a worldwide scale as a defense against pandemic influenza. "
08/01/2013 - "Flublok(®) is the first vaccine containing recombinant protein to be approved for the prevention of seasonal influenza, and is indicated in the USA in adults aged 18-49 years. "
03/09/2011 - "Furthermore, the FluBlok group had a statistically significantly higher seroconversion rate against influenza A/H3N2 compared to the TIV group."
11/27/2015 - "Flublok was non-inferior to AFLURIA in adults ≥50 years of age with respect to expert-adjudicated events of likely hypersensitivity during 30 days following vaccination (Sponsored by Protein Sciences Corporation; ClinicalTrials.gov number NCT01825200)."
11/27/2015 - "The adjudicators determined that six and four subjects on Flublok and AFLURIA, respectively, likely met clinical criteria for hypersensitivity, yielding a difference in incidence between the two vaccine groups of 0.15% (upper bound of 2-sided 95% CI=0.9%). "
11/27/2015 - "Fifty-two subjects reported at least one term possibly representing hypersensitivity, with a slight imbalance of 31 on Flublok and 21 on AFLURIA. "
11/27/2015 - "This blinded, randomized trial of healthy adults ≥50 years of age compared safety of Flublok vs. AFLURIA with respect to pre-specified possible hypersensitivity: "rash," "urticaria," "swelling" and "non-dependent edema;" solicited reactogenicity and unsolicited adverse events. "
11/27/2015 - "The safety and tolerability of Flublok(®), a purified recombinant hemagglutinin seasonal influenza vaccine, was compared to AFLURIA(®) in a randomized, blinded clinical trial in adults ≥50 years of age with attention to hypersensitivity reactions. "
|2.||Influenza Vaccines (FluMist)
|5.||Proteins (Proteins, Gene)
|6.||Blood Coagulation Factors (Coagulation Factor)